Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : QR052107B
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results from the MAD study have shown that QR052107B tablet at doses of 100 and 400 mg QD for 14 days was safe and well tolerated. Only one subject in the placebo treatment group withdrew due to an AE.
Product Name : QR052107B
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : QR052107B
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable